Received: 10 June 2020
Accepted: 11 June 2020
First Online: 26 June 2020
Ethics approval and consent to participate
: The study was approved by the local ethics committee of the Charité - Universitätsmedizin Berlin on April 14 2020. (Reference number: Charité EA1/069/20)Written informed consent is obtained from all patients. If a patient is not able to give written informed consent himself, and a legal representative exists, the consent of the representative will be obtained in advance. For all other patients incapable of informed consent, a legal guardian will be requested immediately. If the patient regains consciousness during the course of the study, he or she will be informed about the study and can subsequently consent to participate in the study. If the patient does not retrospectively agree with the study, his data will be discarded. If the patient does not regain consciousness, the appointed caregiver decides retrospectively on participation in the study. If the patient dies before urgent care could be installed, the personal data of the person concerned will be evaluated in an anonymized manner. In this way, the protection of the personality and the data protection interests of the person concerned are safeguarded. Furthermore, this procedure does not compromise the processing objective of the research project.
: Not applicable
: HS, PE, TS, JVK, TK, JL, AU, CS and CW declare no competing interests. AJ, SB, ST and DKM have received speaker fees from CytoSorbents. KT has received honoraria for lectures and consultations from CytoSorbents Europe.